Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Launched by AGELESSRX · Jul 28, 2025

Keywords

ClinConnect Summary

This early-stage, randomized clinical trial is testing whether very small (microdosed) amounts of a GLP-1 receptor drug called semaglutide, given either as a weekly subcutaneous shot, a weekly sublingual dose, or a placebo, can improve overall health, quality of life, and longevity in healthy adults. The study will follow participants for about six months and look at a mix of outcomes, including self-reported pain and mood, immune health from blood tests, basic metabolic health (like cholesterol and glucose), and data from wearables on sleep, heart-rate patterns, and activity.

Who can join: adults aged 18–65 with a BMI of 20 or higher, who are healthy volunteers and either new or existing AgelessRx patients. Exclusions include pregnancy, recent use of weight-loss meds or bariatric surgery, significant psychiatric illness, or any contraindication to semaglutide. About 150 people will be enrolled at a single site in Ann Arbor, Michigan, and participants will be randomly assigned to one of the three groups, with the study designed so participants do not know which group they’re in. Blood tests occur every 12 weeks, and surveys plus wearable data sharing are used to track progress. The trial is FDA-regulated and currently enrolling by invitation, with completion expected around December 2025. Primary goals focus on health, quality of life, and longevity, with secondary aims including weight management and metabolic health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New or existing AgelessRx patient
• • Adults (aged 18-65)
• • Any sex
• • Any ethnicity
• • BMI ≥ 20 kg/m\^2
• • Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement.
• Exclusion Criteria:
• • Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
• • History of bariatric surgery
• • Use of other weight-loss medications currently or within the past 6 months
• • Contraindications to semaglutide
• • Significant psychiatric illness that may affect participation
• • Pregnant or breastfeeding individuals